About

Recent breakthroughs in cell and gene therapy have revolutionized healthcare. While these innovations hold immense promise for curing previously incurable diseases, their full potential remains unrealized. The rapid development of cell and gene therapy platforms capable of targeting disease at its root has been met with significant challenges in manufacturing and development. The complexity and variability of these therapies have resulted in high costs and production hurdles, limiting their accessibility to patients.

Recognizing these obstacles, Harvard University President Alan Garber convened leaders from academia, industry and leading research hospitals to address these challenges. Their collaborative endeavor resulted in Landmark Bio, an advanced therapy manufacturing company with the explicit mission to translate groundbreaking research into life-changing therapies. Built by drug developers for drug developers, Landmark Bio has emerged as a driving force in the advanced therapy landscape, demonstrating its ability to advance transformative therapies.

“This new state-of-the-art facility will bring together leading innovators from universities, research institutes, hospitals, and industries in the life science community. Landmark Bio will be a platform that enables groundbreaking ideas from our laboratories to be transformed into life-changing therapies.

The work here will facilitate access to the most promising approaches to preventing and treating illness, thanks to advances in biomanufacturing technologies.”

—Alan M. Garber, President of Harvard University,
Founding Board Chair of Landmark Bio